Want to see BDMD full AI Analyst Report?
BDMD Stock Chart & Stats
$1.18
$0.13(1.73%)
At close: 4:00 PM EST
$1.18
$0.13(1.73%)
Day’s Range― - ―
52-Week Range$0.66 - $3.70
Previous Close$7.55
Volume323.07K
Average Volume (3M)53.24K
Market Cap
$24.04M
Enterprise Value$49.15M
Total Cash (Recent Filing)$289.08K
Total Debt (Recent Filing)$14.22M
Price to Earnings (P/E)―
Beta-0.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,002,370
10 Day Avg. Volume92,747
30 Day Avg. Volume53,244
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)1.68
P/FCF Ratio-27.26
Enterprise Value/Market Cap2.04
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit2.34
Enterprise Value/Ebitda-3.77
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
2026 Revenue And Profit RecoveryThe first-half 2026 rebound indicates that international expansion and licensing activity can restore growth after the prior-year downturn. A return to positive earnings, even at a modest level, improves operating resilience and provides a foundation for rebuilding profitability.
High Gross Margins And Cost DisciplineVery high gross margins provide substantial potential to convert additional revenue into earnings when expenses are controlled. The sharp reduction in operating costs demonstrates improved cost discipline, which could support more durable profitability as commercial activity expands.
International Product And Technology ExpansionThe IRE partnership adds a next-generation ablation platform and gives Baird Medical worldwide commercialization rights, while recent international registrations broaden its market access. These developments strengthen the company’s product pipeline and geographic growth potential.
Bears Say
Persistently Negative Cash GenerationRepeatedly negative operating and free cash flow shows that reported business activity has not yet translated into internally funded operations. If this persists, the company may need external capital to support commercialization, increasing funding dependence and reducing financial flexibility.
Severe 2025 Financial DeteriorationThe 2025 collapse in revenue and profitability indicates substantial earnings volatility and weak recent quality of earnings. Although first-half 2026 results improved, the sharp prior deterioration demonstrates that the recovery remains important to sustaining operations and rebuilding investor confidence.
Declining Equity CushionLeverage is described as manageable, but declining equity reduces the balance sheet cushion available to absorb further losses. Continued negative returns could weaken financial flexibility over time and constrain the company’s ability to fund growth without relying on external capital.
Baird Medical Investment Holdings News
BDMD FAQ
What was Baird Medical Investment Holdings’s price range in the past 12 months?
Baird Medical Investment Holdings lowest stock price was $0.66 and its highest was $3.70 in the past 12 months.
What is Baird Medical Investment Holdings’s market cap?
Baird Medical Investment Holdings’s market cap is $24.04M.
When is Baird Medical Investment Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Baird Medical Investment Holdings’s earnings last quarter?
Currently, no data Available
Is Baird Medical Investment Holdings overvalued?
According to Wall Street analysts Baird Medical Investment Holdings’s price is currently Overvalued.
Does Baird Medical Investment Holdings pay dividends?
Baird Medical Investment Holdings does not currently pay dividends.
What is Baird Medical Investment Holdings’s EPS estimate?
Baird Medical Investment Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Baird Medical Investment Holdings have?
Baird Medical Investment Holdings has 32,002,370 shares outstanding.
What happened to Baird Medical Investment Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Baird Medical Investment Holdings?
Currently, no hedge funds are holding shares in BDMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Baird Medical Investment Holdings
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.
Technical Analysis
Ownership Overview
―
Insiders
0.08% Mutual Funds
0.78% Other Institutional Investors
99.14% Public Companies and
Individual Investors